Cochrane · systematic review · CD012284
Growth hormone therapy for people with thalassaemia
Ngim, CF, Lai, NM, Hong, JYH, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 6 · 85.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsGrowth hormone for people with thalassaemia
Population: people with thalassaemia (any age)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Final height and change in height | no estimate extracted | NR | No studies |
Adverse effects Oral glucose tolerance test (mg/dL) (at one year) | no estimate extracted | 1 study · 20 participants | Moderate Downgraded: imprecision |
Height SDS(at one year) | no estimate extracted | 1 study · 20 participants | Moderate Downgraded: imprecision |
Change in height SDS (difference between baseline and final visit at one year) | no estimate extracted | 1 study · 20 participants | Moderate Downgraded: imprecision |
Height velocity (cm/year) | no estimate extracted | 1 study · 20 participants | Moderate Downgraded: imprecision |
Height velocity SDS | no estimate extracted | 1 study · 20 participants | Moderate Downgraded: imprecision |
Change in height velocity SDS (difference between baseline and final visit at one year) | no estimate extracted | 1 study · 20 participants | Moderate Downgraded: imprecision |